Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM +2.08%72 Cash Ratio is 0.02 as of Mar. 2026, which is 50% below its 10-year median of 0.04. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 439 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 97.72% on this metric.
Orion Pharma has a Cash Ratio of 0.02. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Orion Pharma's Cash Ratio or its related term are showing as below:
DHA:ORIONPHARM'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.37
Current: 0.02
During the past 12 years, Orion Pharma's highest Cash Ratio was 0.37. The lowest was 0.01. And the median was 0.04.
DHA:ORIONPHARM's Cash Ratio is ranked worse than 97.72% of 439
companies
in the Utilities - Independent Power Producers industry
Industry Median: 0.44
vs DHA:ORIONPHARM: 0.02
Orion Pharma (DHA:ORIONPHARM) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Orion Pharma Cash Ratio Related Terms
Orion Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Cash Ratio Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Cash Ratio vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Cash Ratio of 0.02 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orion Pharma and its competitors. This is 50% below median its historical median of 0.04. Over the past decade, Orion Pharma's Cash Ratio has ranged from 0.01 to 0.37. According to the industry distribution chart, Orion Pharma ranks #429 out of 439 companies in the Utilities - Independent Power Producers industry, placing it in the top 97.7%.
Is Orion Pharma's Cash Ratio too high?
Orion Pharma's current Cash Ratio of 0.02 is 50% below median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.37. The Utilities - Independent Power Producers industry median Cash Ratio is 0.44. Orion Pharma's value of 0.02 is 95.5% below this industry median. Based on the distribution chart, Orion Pharma ranks #429 out of 439 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Cash Ratio compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #429 out of 439 companies for Cash Ratio. This places Orion Pharma in the lower half of its industry. The industry median Cash Ratio is 0.44. Orion Pharma's value of 0.02 is 95.5% below this benchmark. Historically, Orion Pharma's own Cash Ratio has ranged from 0.01 to 0.37 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.44, Orion Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for an Utilities - Independent Power Producers company?
The median Cash Ratio among Utilities - Independent Power Producers companies is 0.44, based on 439 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Cash Ratio of 0.02 is 95.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Cash Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Cash Ratio is 0.02, which is 50% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.00, compared to a current price of BDT29.40 — trading 47% above its estimated fair value. The current Cash Ratio is 0.02, which is 50% below median its 10-year median of 0.04 and 95.5% below the Utilities - Independent Power Producers industry median of 0.44. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Cash Ratio is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT29.40 is trading 47% above its estimated GF Value™ of BDT20.00.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Cash Ratio: 0.02 (50% below median its 10-year median of 0.04)
GF Value™: BDT20.00 vs. price of BDT29.40 (47% above fair value)
Industry Position: 95.5% below the Utilities - Independent Power Producers median (#429 of 439)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
